Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
The availability of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as
liraglutide and semaglutide, and a GLP-1 and glucose dependent insulinotropic polypeptide …
liraglutide and semaglutide, and a GLP-1 and glucose dependent insulinotropic polypeptide …
[HTML][HTML] Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks
Background This review investigates the side effects of glucagon-like peptide-1 receptor
agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for …
agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for …
Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study
BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective in
diabetes and obesity, reducing hyperglycemia by increasing insulin release and delaying …
diabetes and obesity, reducing hyperglycemia by increasing insulin release and delaying …
[HTML][HTML] Real-world impact of GLP-1 receptor agonists on endoscopic patient outcomes in an ambulatory setting: a retrospective study at a large tertiary center
Background: Glucagon-like peptide receptor agonists (GLP-1 RAs) are associated with
delayed gastric emptying and may increase the risk of aspiration due to retained gastric …
delayed gastric emptying and may increase the risk of aspiration due to retained gastric …
Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: A systematic review & meta-analysis
Background and aims Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to
cause delayed gastric emptying, however the effect on clinical outcomes during upper …
cause delayed gastric emptying, however the effect on clinical outcomes during upper …
[HTML][HTML] Impact of GLP-1 receptor agonists in gastrointestinal endoscopy: an updated review
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become one of the most
popular medications for patients with diabetes and obesity. Due to their effects on gut motility …
popular medications for patients with diabetes and obesity. Due to their effects on gut motility …
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
DJ Drucker - Diabetes Care, 2024 - Am Diabetes Assoc
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2
diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA …
diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA …
Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) affect gastrointestinal
motility, slowing gastric emptying and colonic transit. GLP-1RAs have an impact on gastric …
motility, slowing gastric emptying and colonic transit. GLP-1RAs have an impact on gastric …
Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual GLP-1-and
glucose-dependent insulinotropic polypeptide receptor co-agonist tirzepatide (referred to …
glucose-dependent insulinotropic polypeptide receptor co-agonist tirzepatide (referred to …
Semaglutide is an independent predictor of retained solid gastric contents, but same-day colonoscopy mitigates effect
H Korlipara, J Chua, A Buckholz, J Jamison… - … and Innovations in …, 2024 - Elsevier
Abstract BACKGROUND AND AIMS Glucagon-like peptide-1 receptor agonists are
commonly prescribed for diabetes and obesity; however, their use may complicate …
commonly prescribed for diabetes and obesity; however, their use may complicate …